SCHEMBL23345010

SCHEMBL23345010

CC(=O)N1CCC(OC2CC2)(C(C)(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.36
CYP1A2 P05177 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
USP2 O75604 1/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
EPHX1 P07099 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GAA P10253 1/20 0.32
GFER P55789 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23345229 0.90 CYP4F2 (0.36) EPHX2CYP4F2CYP4A11ALDH1A1MAPK1
SCHEMBL23344999 0.79 CYP1A2 (0.39) EPHX2CYP1A2TDP1USP2CYP4F2
SCHEMBL21997014 0.78 NR1H2 (0.34)
SCHEMBL21997013 0.78 NR1H2 (0.34)
SCHEMBL24597128 0.77 EPHX2 (0.42) EPHX2CYP1A2TDP1USP2EPHX1
SCHEMBL23345230 0.72 CYP4F2 (0.40) CYP1A2TDP1USP2CYP4F2CYP4A11
SCHEMBL26806869 0.71 SMN1; SMN2 (0.39) EPHX2CYP1A2TDP1USP2CYP4F2
SCHEMBL23309174 0.70 CYP1A2 (0.44) EPHX2CYP1A2TDP1USP2ALDH1A1
SCHEMBL23077821 0.69 CYP1A2 (0.43) EPHX2CYP1A2TDP1USP2ALDH1A1
SCHEMBL23309207 0.69 CYP1A2 (0.43) EPHX2CYP1A2TDP1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 EPHX2 2126/4885CYP1A2 1997/4885TDP1 2014/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 EPHX2 1872/4885CYP1A2 2086/4885TDP1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.